Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5886)
Drug Name
Infigratinib
Synonyms
Infigratinib|NVP-BGJ398|872511-34-7|BGJ398|BGJ-398|Truseltiq|BGJ 398|Infigratinib [INN]|Infigratinib free base|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea|Infigratinib [USAN]|BGJ398 (NVP-BGJ398)|MVP-BGJ398|UNII-A4055ME1VK|NVP-BGJ398(Infigratinib)|A4055ME1VK|CHEBI:63451|872511-34-7 (free base)|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea|Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-((4-(4-ethyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)-N-methyl-|CHEMBL1834657|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea.|3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea|Infigratinib (BGJ398)|Infigratinib (USAN/INN)|Infigratinib [USAN:INN]|D03LWG|NVP-BGJ389|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea|MLS006010953|INFIGRATINIB [WHO-DD]|SCHEMBL374435|GTPL7877|CHEMBL1852688|DTXSID70236238|EX-A057|QADPYRIHXKWUSV-UHFFFAOYSA-N|HMS3295O21|AMY10737|BCP03602|BGJ398 - NVP-BGJ398|BDBM50355393|FD5035|MFCD22123241|NSC764487|s2183|WHO 10032|AKOS025149513|AKOS032949944|BCP9000399|CS-0586|DB11886|NSC-764487|SB16612|NCGC00274030-01|NCGC00274030-11|3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea|AC-28417|AS-16290|HY-13311|SMR004702757|BCP0726000187|FT-0699366|D11589|J-510477|BRD-K42728290-001-01-8|Q27075200|07J|3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea|N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1- PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYLUREA
Pharmaceutical Properties Molecular Weight 560.5 Topological Polar Surface Area 95.1
Heavy Atom Count 38 Rotatable Bond Count 8
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
53235510
Formula
C26H31Cl2N7O3
Canonical SMILES
CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl
InChI
InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
InChIKey
QADPYRIHXKWUSV-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Infigratinib M1 DM005086 N. A. Oxidation - O-Demethylation 1 [4]
Infigratinib M11 DM005089 N. A. Unclear 1 [4]
Infigratinib M2 DM005087 N. A. Oxidation - N-Dealkylation 1 [4]
Infigratinib M3 DM005088 N. A. Other reaction - N-ethyl piperazine ring 1 [4]
Unclear DM009999 N. A. Oxidation - Hydrolyzationn 1 [1] , [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR005514 Infigratinib Unclear Oxidation - Hydrolyzationn CYP3A4 ... [1], [2]
MR005515 Infigratinib Infigratinib M1 Oxidation - O-Demethylation Unclear [4]
MR005516 Infigratinib Infigratinib M2 Oxidation - N-Dealkylation Unclear [4]
MR005517 Infigratinib Infigratinib M3 Other reaction - N-ethyl piperazine ring Unclear [4]
MR005518 Infigratinib Infigratinib M11 Unclear Unclear [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2J2 (CYP2J2) DME0031 Homo sapiens
CP2J2_HUMAN
1.14.14.24
[1] , [2]
Cytochrome P450 2J2 (CYP2J2) DME0031 Homo sapiens
CP2J2_HUMAN
1.14.14.24
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[1] , [2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[1]
Dimethylaniline oxidase 3 (FMO3) DME0039 Homo sapiens
FMO3_HUMAN
1.14.13.8
[3]
References
1 Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4
2 Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
3 LABEL:Infigratinib
4 Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.